Similar Papers

Paper Title
Journal
Date
Author
Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
Pankit Vachani ... Srdan Verstovsek
Blood | VOL. 138
Pankit Vachani, et. al.Pankit Vachani ... Srdan Verstovsek
05 Nov 2021
MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
John Mascarenhas ... Srdan Verstovsek
Blood | VOL. 136
John Mascarenhas, et. al.John Mascarenhas ... Srdan Verstovsek
05 Nov 2020
The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Harinder Gill ...
Blood | VOL. 138
Harinder Gill, et. al.Harinder Gill ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.